ARPC3P3

Across TCGA pan-cancer cohorts, ARPC3P3 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ARPC3P3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ARPC3P3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARPC3P3 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

LIHC, HNSC, and KIRP are the cancer types where ARPC3P3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARPC3P3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.633	<.001	9	view →
HNSC	Male	All	+0.455	<.001	9	view →
KIRP	All	All	+0.394	<.001	8	view →
BRCA	All	III,IV	+0.566	<.001	6	view →
KIRC	Male	All	+0.430	<.001	6	view →
COAD	Female	All	+0.770	.001	5	view →
LUAD	All	All	+0.443	.002	5	view →
BLCA	Male	III,IV	+0.740	.002	4	view →
PAAD	All	All	−0.737	.027	4	view →
STAD	Female	All	+0.687	.009	4	view →
UCEC	All	All	+0.491	.020	4	view →
THCA	All	III,IV	+0.340	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ARPC3P3–LIHC

Open the LIHC breakdown →